HAMILTON, ON and BOSTON, June 16, 2023 /PRNewswire/ Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision. | June 16, 2023
HAMILTON, ON and BOSTON, June 7, 2023 /PRNewswire/ Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision. | June 7, 2023
HAMILTON, ON and BOSTON, May 31, 2023 /PRNewswire/ Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision. | May 31, 2023
/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.
FPI-2265 (Ac-PSMA I&T) program enrolling patients and on track for Q1 2024 update Preliminary Phase 1 data for FPI-1434 expected to be reported at the Society.